patients that present a relapse within the previously irradiated volume can be included in this trial. These patients will receive re-irradiation according to clinical guidelines and hyperthermia as study intervention. According to tumor location hyperthermia can either be performed by microwave or by capacitive devices.
The primary endpoint of this study is non-inferiority of re-irradiation compared to the initial course of radiotherapy (calculated as time to local failure).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
prior radiotherapy of the treatment side with a treatment dose \> 30 Gray (Gy) EQD2 (calculated with alpha/beta value of 9)
local/ regional / or oligometastatic tumor recurrence. Maximum number of three macroscopic tumor lesions with at least one of them receiving prior radiotherapy
macroscopic tumor recurrence
side of recurrence is amenable to hyperthermia (abdomen, pelvis, extremities, spine, cervical lymphnodes)
planned re-irradiation dose of at least 40 Gy EQD2 (calculated with alpha/beta value of 9)
You may not be if
\>3 macroscopic tumor lesion
brain metastases
recurrence is amenable to local ablative radiotherapy (brachytherapy or stereotactic radiotherapy)
recurrence region is not amenable to hyperthermia (lung, liver, mediastinum)
contraindications for hyperthermia (serious cariovascular disease, ICD or larger implants at the treatment site)
psychiatric disorders that impede proper informed consent
serious comorbidities with very limited prognosis quo ad vitam
